57 results on '"Annis, James"'
Search Results
2. Supplementary Figure Legends from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
3. Supplementary Figure 2 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
4. Data from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
5. Supplementary Figure 1 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
6. Supplementary Figure Legends from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
7. Supplementary Tables 1-3 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
8. Supplementary Tables 1-3 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
9. Supplementary Figure 2 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
10. Data from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
11. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
12. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
13. Supplementary Tables S18-20 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
14. Supplementary Table Legends from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
15. Supplementary Table S21 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
16. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
17. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
18. Supplementary Figure S1 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
19. Supplementary Table Legends from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
20. Supplementary Figure S4 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
21. Supplementary Tables S1-8 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
22. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
23. Supplementary Figure S3 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
24. Supplementary Figure S2 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
25. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
26. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
27. Supplementary Tables S1-8 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
28. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
29. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
30. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
31. Supplementary Figure S2 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
32. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
33. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
34. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
35. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
36. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
37. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
38. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
39. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
40. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
41. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
42. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
43. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
44. Supplementary Table S21 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
45. Supplementary Figure S1 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
46. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
47. Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
48. Supplementary Figure S4 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
49. Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
50. Supplementary Figure S3 from Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.